Global PEG-modified Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global PEG-modified Drugs Market Research Report 2024
Polyethylene glycol modified drug refers to a method of drug modification that combines polyethylene glycol molecules with drug molecules to improve the properties, pharmacokinetics and pharmacodynamic properties of drugs. This modification is often used to improve drug solubility, stability, bioavailability, and drug distribution.
According to MRAResearch’s new survey, global PEG-modified Drugs market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole PEG-modified Drugs market research.
Key companies engaged in the PEG-modified Drugs industry include Merck Sharp & Dohme, Baxalta Inc., Amgen Inc., Roche, UCB S.A., Enzon, Horizon Pharma Plc, Biogen Inc. and Qilu Pharmaceutical Co., Ltd., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of PEG-modified Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole PEG-modified Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global PEG-modified Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Merck Sharp & Dohme
Baxalta Inc.
Amgen Inc.
Roche
UCB S.A.
Enzon
Horizon Pharma Plc
Biogen Inc.
Qilu Pharmaceutical Co., Ltd.
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Changchun Genescience Pharmaceutical Co., Ltd.
Xiamen Amoytop Biotech Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Hansoh Pharmaceuticak Group Co.,Ltd.
SunBio
Xiamen Sano banger Biotechnology Co., Ltd
Segment by Type
PEG Amidation
PEGylation
PEG Peptidation
PEG Etherification
Other Combinations
Cancer Treatment
Diabetes Treatment
Immunomodulatory
Anti-inflammatory Treatment
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The PEG-modified Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global PEG-modified Drugs market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole PEG-modified Drugs market research.
Key companies engaged in the PEG-modified Drugs industry include Merck Sharp & Dohme, Baxalta Inc., Amgen Inc., Roche, UCB S.A., Enzon, Horizon Pharma Plc, Biogen Inc. and Qilu Pharmaceutical Co., Ltd., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of PEG-modified Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole PEG-modified Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global PEG-modified Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck Sharp & Dohme
Baxalta Inc.
Amgen Inc.
Roche
UCB S.A.
Enzon
Horizon Pharma Plc
Biogen Inc.
Qilu Pharmaceutical Co., Ltd.
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Changchun Genescience Pharmaceutical Co., Ltd.
Xiamen Amoytop Biotech Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Hansoh Pharmaceuticak Group Co.,Ltd.
SunBio
Xiamen Sano banger Biotechnology Co., Ltd
Segment by Type
PEG Amidation
PEGylation
PEG Peptidation
PEG Etherification
Other Combinations
Segment by Application
Cancer Treatment
Diabetes Treatment
Immunomodulatory
Anti-inflammatory Treatment
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The PEG-modified Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source